Lewud-A Tablet SR is a combination pharmaceutical formulation containing Ambroxol 75 mg, Levocetirizine 5 mg, and Montelukast 10 mg, designed for the management of respiratory conditions characterized by mucus hypersecretion, allergic symptoms, and bronchoconstriction. Ambroxol, a mucolytic agent, facilitates the breakdown and clearance of mucus from the respiratory tract, improving airway patency and easing expectoration. Levocetirizine, a selective second-generation antihistamine, effectively alleviates allergic manifestations such as rhinorrhea, sneezing, and nasal congestion by competitively inhibiting peripheral H1 histamine receptors, with minimal sedative effects. Montelukast, a leukotriene receptor antagonist, targets cysteinyl leukotriene receptors, thereby reducing inflammation, bronchospasm, and airway hyperresponsiveness commonly observed in asthma and allergic rhinitis. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, enhancing patient compliance by reducing dosing frequency. Lewud-A Tablet SR is indicated for adjunctive treatment in chronic respiratory diseases including asthma, chronic bronchitis, and allergic rhinitis where a combination of mucolytic, antihistaminic, and anti-inflammatory actions is warranted. It should be used under medical supervision, considering contraindications such as hypersensitivity to any component, and potential drug interactions. Adverse effects are generally mild but may include gastrointestinal disturbances, headache, or drowsiness.